首页> 中文期刊> 《现代检验医学杂志》 >血红素结合蛋白研究进展

血红素结合蛋白研究进展

         

摘要

Hemopexin(Hp),also called hoptoglobinand,haptoglobin,is mainly expressed in liver,and belongs to acute phase reactants. Hp has specific ability to combine with free hemoglobin(former porphyrin Ⅸ ,heme). When widely hemolysis,free hemoglobin in blood circulation biodegradates for globin and heme tow parts. Heme is insoluble in water,but can be transported to the liver combined with Hp. The research indicates that,in many diseases about oxidative stress and inflammation, such as diabetes,breast cancer and malignant melanoma,the expression of hemopexin changes.%血红素结合蛋白(hemopexin,Hp)又称结合珠蛋白、触珠蛋白,是肝脏合成的一种急性时相反应蛋白.其和游离血红素(原卟啉Ⅸ,heme)有特异结合能力.当广泛溶血时,循环中游离的血红蛋白可降解为珠蛋白和血红素两部分.血红素不溶于水,可与Hp结合成复合物而运输到肝.研究表明,在许多与氧化应激、炎症相关的疾病中,例如糖尿病、乳腺癌、恶性黑色素瘤,血红素结合蛋白表达均发生改变.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号